Short answer
JOINT Corp (JYNT) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q2 2026 results for quarter ended June 30, 2026 announced August 6, 2026.
JOINT Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced August 6, 2026
- Full financial figures and management commentary available in Exhibit 99.1 press release
Item 7.01 · Regulation FD Disclosure
- Earnings presentation posted at ir.thejoint.com as Exhibit 99.2
- Presentation supports the August 6, 2026 earnings conference call and investor discussions
- Investors should review Exhibit 99.2 for management’s earnings-period commentary and financial highlights
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $15.2M, up 14%, while system-wide sales fell 3.7% and comp sales remained negative at (2.8%)
- Continuing-operations net loss narrowed to $251K from $1.0M, with Adjusted EBITDA rising to $1.5M from $88K
- Operating cash flow reached $2.2M and free cash flow $1.9M, supporting $677K of share repurchases and three RD territory buybacks
- Refranchising substantially complete, leaving 896 franchised clinics and 45 company-owned or managed clinics at June 30
- 2026 guidance reaffirmed: $519M to $552M system-wide sales, $12.5M to $13.5M Adjusted EBITDA, and 22 to 26 new franchised clinics
Item EX-99.2 · Exhibit EX-99.2
- Q2 revenue $15.2M, up $1.9M year over year, while consolidated net income reached $0.7M from $0.1M
- Continuing-operations Adjusted EBITDA $1.5M, up $1.4M, signaling benefits from the capital-light franchisor transition
- System-wide sales $128.0M, down 3.7%, with comparable sales declining 2.8% but improving 140 basis points sequentially
- Free cash flow $1.9M, up from $0.4M, supported by operating cash flow growth of 152% to $2.2M
- 2026 guidance reiterated: system-wide sales $519M to $552M, Adjusted EBITDA $12.5M to $13.5M, and 22 to 26 new franchised clinics
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other JOINT Corp 8-K filings
Get the next JYNT 8-K as it lands
Follow JYNT for push alerts, or ask the research agent what this filing means.